Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 17;7:264. doi: 10.1186/s40425-019-0737-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 3 — Association of TET1 status and clinical outcomes in the discovery cohort. a. Histogram depicting proportions of patients achieved objective response (ORR) in TET1-MUT and TET1-WT groups. (n = 515; 4 patients with best overall response not evaluable). b. Histogram depicting proportions of patients derived durable clinical benefit (DCB) in TET1-MUT and TET1-WT groups. (n = 495; 24 patients with durable clinical benefit not evaluable). c. Kaplan-Meier estimates of progression-free survival (PFS) in the discovery cohort comparing patients with TET1-MUT with their respective WT counterparts. (n = 519). d. Kaplan-Meier estimates of overall survival (OS) in the discovery cohort comparing patients with TET1-MUT with their respective WT counterparts. (n = 490; 29 patients with no OS information available)